MedTrace Logo

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NCT02648724 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2022-06-22

Study results available
· View outcomes & findings →

Summary

This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.

Conditions

  • Oncology
  • MET Gene Amplification
  • NSCLC
  • MET Gene Mutation
  • Non Small Cell Lung Cancer

Interventions

DRUG

Sym015

Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

Sponsors & Collaborators

  • Symphogen A/S

    lead INDUSTRY

Principal Investigators

  • Amita Patnaik, MD, FRCP(C) · South Texas Accelerated Research Therapeutics, LLC

  • David Ross Camidge, MD, PhD · University of Colorado, Denver

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Hong Kong
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648724 on ClinicalTrials.gov